<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2015-11-2-153-158</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-121</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PREVENTIVE CARDIOLOGY AND PUBLIC HEALTH</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРОФИЛАКТИЧЕСКАЯ КАРДИОЛОГИЯ И ОБЩЕСТВЕННОЕ ЗДОРОВЬЕ</subject></subj-group></article-categories><title-group><article-title>HYPOLIPIDEMIC THERAPY IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN 2004-2010 ACCORDING TO THE PROGNOZ IBS REGISTER</article-title><trans-title-group xml:lang="ru"><trans-title>ГИПОЛИПИДЕМИЧЕСКАЯ ТЕРАПИЯ У ПАЦИЕНТОВ С ХРОНИЧЕСКОЙ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА В 2004-2010 ГГ. ПО ДАННЫМ РЕГИСТРА «ПРОГНОЗ ИБС»</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Толпыгина</surname><given-names>С. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Tolpygina</surname><given-names>S. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., в.н.с. отдела профилактической фармакотерапии</p><p>101990, Москва, Петроверигский пер., 10</p></bio><bio xml:lang="en"><p>Petroverigsky per. 10, Moscow, 101990 Russia</p></bio><email xlink:type="simple">stolpygina@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полянская</surname><given-names>Ю. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Polyanskaya</surname><given-names>Yu. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>м.н.с. того же отдела</p><p>101990, Москва, Петроверигский пер., 10</p></bio><bio xml:lang="en"><p>Petroverigsky per. 10, Moscow, 101990 Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Марцевич</surname><given-names>С. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Martsevich</surname><given-names>S. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, руководитель того же отдела</p><p>101990, Москва, Петроверигский пер., 10</p></bio><bio xml:lang="en"><p>Petroverigsky per. 10, Moscow, 101990 Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Государственный научно-исследовательский центр профилактической медицины</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Research Centre for Preventive Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>22</day><month>09</month><year>2015</year></pub-date><volume>11</volume><issue>2</issue><fpage>153</fpage><lpage>158</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Tolpygina S.N., Polyanskaya Y.N., Martsevich S.Y., 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="ru">Толпыгина С.Н., Полянская Ю.Н., Марцевич С.Ю.</copyright-holder><copyright-holder xml:lang="en">Tolpygina S.N., Polyanskaya Y.N., Martsevich S.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/121">https://www.rpcardio.online/jour/article/view/121</self-uri><abstract><sec><title>Aim</title><p>Aim. To evaluate the frequency of prescription, efficacy and patients adherence to statin therapy in a cohort of patients with ischemic heart disease (IHD), confirmed by coronary angiography data, during the period from 2004 to 2010 based on the data from the PROGNOZ IBS register.</p></sec><sec><title>Material and methods</title><p>Material and methods. The PROGNOZ IBS register database was used in the study. The data of 550 patients from a cohort of patients with the confirmed IHD, who had undergone coronary angiography from 2004 to 2008 (303 of them were on the follow-up visit) were included in the final analysis.</p></sec><sec><title>Results</title><p>Results. Low frequency of statins prescription in patients with stable IHD prior to hospitalization in 2004-2007 and a significant improvement of its quality during the stay in a specialized cardiology unit were revealed in the PROGNOZ IBS register. The frequency of statin prescription at discharge increased from 10% to 85.5% (in most cases original drugs were used), but the prescribed doses were usually inadequate. Target blood lipid levels were not achieved in the majority of patients. The level of low density cholesterol &lt;2.5 mmol/L at discharge was present in 6.3% of the patients (the short period of hospitalization insufficient for the achievement of statins maximum effect should be taken into consideration). 67% of patients had good adherence to lipid-lowering therapy 3.9 years after the admission, however, the original drugs had been replaced by a variety of generics in most patients. The efficacy of the therapy was inadequate: the target levels of total cholesterol (&lt;4.5 mmol/L) and low density cholesterol (&lt;2.5 mmol/L) were achieved in 40% of patients, of low density cholesterol (&lt;2.0 mmol/l) - in 15.8%.</p></sec><sec><title>Conclusion</title><p>Conclusion. Low frequency of statins prescription in patients with stable IHD before the admission to the hospital, its significant growth during the stay and its reduction after the discharge were revealed. The treatment efficacy was low at all stages of the observation. Patients' adherence to statin therapy in the outpatient setting remains inadequate.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Цель</title><p>Цель. Оценить частоту назначения, эффективность и приверженность лечению статинами в когорте пациентов с ишемической болезнью сердца (ИБС), подтвержден-ной данными коронарной ангиографии (КАГ), за период с 2004 по 2010 гг. на основании данных регистра ПРОГНОЗ ИБС.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследовании использовалась база данных регистра ПРОГНОЗ ИБС. В окончательный анализ были включены данные 550 пациентов из ко-горты больных с доказанной ИБС, перенесших процедуру КАГ за период 2004-2008 гг. в ГНИЦ ПМ, из которых 303 явились на контрольный визит.</p></sec><sec><title>Результаты</title><p>Результаты. В регистре ПРОГНОЗ ИБС выявлена низкая частота назначения гиполипидемических препаратов у больных со стабильной ИБС до госпитализации в 2004-2007 гг., и значительное улучшение ее качества в период пребывания в специализированном кардиологическом стационаре. При выписке частота назначения стати-нов выросла с 10% до 85,5% (в большинстве случаев – оригинальные препараты), однако они применялись, как правило, в неадекватных дозах. У большинства па-циентов не были достигнуты целевые уровни липидов крови. Уровень холестерина липопротеидов низкой плотности (ХС ЛПНП) &lt;2,5 ммоль/л при выписке имели 6,3% пациентов (следует учитывать короткий срок госпитализации, недостаточный для достижения максимального эффекта статинов). Через 3,9 года после госпитализа-ции приверженными назначенному лечению статинами оказались 67% пациентов, однако у большинства пациентов оригинальные препараты были заменены на раз-личные дженерики. Эффективность терапии была недостаточной: целевые значения общего холестерина &lt;4,5 ммоль/л и ХС ЛПНП &lt;2,5 ммоль/л были достигнуты у 40% больных, ХС ЛПНП &lt;2,0 ммоль/л достигли лишь 15,8%.</p></sec><sec><title>Заключение</title><p>Заключение. Выявлена низкая частота назначения гиполипидемических препаратов у больных со стабильной ИБС до госпитализации, ее значительный рост в период пребывания в специализированном стационаре и снижение после выписки. Эффективность терапии была низкой на всех этапах наблюдения. Остается недостаточ-ной приверженность пациентов лечению статинами в амбулаторных условиях.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>регистр</kwd><kwd>хроническая ишемическая болезнь сердца</kwd><kwd>лечение</kwd><kwd>гиполипидемическая терапия</kwd><kwd>статины</kwd><kwd>эффективность</kwd><kwd>приверженность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>register</kwd><kwd>chronic ischemic heart disease</kwd><kwd>treatment</kwd><kwd>hypolipidemic therapy</kwd><kwd>statins</kwd><kwd>efficiency</kwd><kwd>adherence</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study. Lancet 1994: 344: 1383-9.</mixed-citation><mixed-citation xml:lang="en">Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study. Lancet 1994: 344: 1383-9.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Saks FM, Pfeffer MA, Moye LA, et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.</mixed-citation><mixed-citation xml:lang="en">Saks FM, Pfeffer MA, Moye LA, et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.</mixed-citation><mixed-citation xml:lang="en">The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.</mixed-citation><mixed-citation xml:lang="en">Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sever PS, Dahlof B, Poulter NR, et al for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149-58.</mixed-citation><mixed-citation xml:lang="en">Sever PS, Dahlof B, Poulter NR, et al for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149-58.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Shepherd L, Blauw GJ, Murphy MB, et al. PROSPER study group. PROspective study of pravastatin in the elderly at risk. Pravastatin in elederly individuals at risk vascular disease (PROSPER): a randomized controlled trial. Lancet 2002: 360; 1623-30.</mixed-citation><mixed-citation xml:lang="en">Shepherd L, Blauw GJ, Murphy MB, et al. PROSPER study group. PROspective study of pravastatin in the elderly at risk. Pravastatin in elederly individuals at risk vascular disease (PROSPER): a randomized controlled trial. Lancet 2002: 360; 1623-30.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Amarenco P, Bogousslavsky J, Amarenco P et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59.</mixed-citation><mixed-citation xml:lang="en">Amarenco P, Bogousslavsky J, Amarenco P et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004; 364: 685-96.</mixed-citation><mixed-citation xml:lang="en">Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004; 364: 685-96.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Diagnostics and correction of lipid disorders for the prevention and treatment of atherosclerosis. Russian recommendations. Cardiovascular Therapy and Prevention 2007; 6 (suppl 3): 1-35. Russian (Ди-агностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеро-склероза. Российские рекомендации. Kardiovaskulyarnaya Terapiya i Profilaktika 2007; 6 (прило-жение 3): 1-35).</mixed-citation><mixed-citation xml:lang="en">Diagnostics and correction of lipid disorders for the prevention and treatment of atherosclerosis. Russian recommendations. Cardiovascular Therapy and Prevention 2007; 6 (suppl 3): 1-35. Russian (Ди-агностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеро-склероза. Российские рекомендации. Kardiovaskulyarnaya Terapiya i Profilaktika 2007; 6 (прило-жение 3): 1-35).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Susekov AB, Zubarev MYu, Deev AD, et al. The main results of the Moscow Research on statins (Moscow Statin Survey, MSS). Serdtse 2006, 6: 324-328. Russian (Сусеков А В, Зубарева М.Ю, Деев А.Д, и др. Основные результаты Московского Исследования по Статинам (Moscow Statin Survey, MSS). Сердце 2006, 6: 324-328).</mixed-citation><mixed-citation xml:lang="en">Susekov AB, Zubarev MYu, Deev AD, et al. The main results of the Moscow Research on statins (Moscow Statin Survey, MSS). Serdtse 2006, 6: 324-328. Russian (Сусеков А В, Зубарева М.Ю, Деев А.Д, и др. Основные результаты Московского Исследования по Статинам (Moscow Statin Survey, MSS). Сердце 2006, 6: 324-328).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ershova AI, Meshkov AN Jakushin SS, et al. Diagnosis and treatment of patients with severe hypercholesterolemia in real outpatient practice (according to the register REKVAZA). Ration Pharmacother Cardiol 2014; 10 (6): 612-6. Russian (Ершова А.И., Мешков А.Н., Якушин С.С., и др. Диагно-стика и лечение больных с выраженной гиперхолестеринемией в реальной амбулаторно- по-ликлинической практике (по данным регистра РЕКВАЗА). Рациональная Фармакотерапия в Кар-диологии 2014;10(6):612-6).</mixed-citation><mixed-citation xml:lang="en">Ershova AI, Meshkov AN Jakushin SS, et al. Diagnosis and treatment of patients with severe hypercholesterolemia in real outpatient practice (according to the register REKVAZA). Ration Pharmacother Cardiol 2014; 10 (6): 612-6. Russian (Ершова А.И., Мешков А.Н., Якушин С.С., и др. Диагно-стика и лечение больных с выраженной гиперхолестеринемией в реальной амбулаторно- по-ликлинической практике (по данным регистра РЕКВАЗА). Рациональная Фармакотерапия в Кар-диологии 2014;10(6):612-6).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Coronary Drug Project Group. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980;303:1038-41.</mixed-citation><mixed-citation xml:lang="en">Coronary Drug Project Group. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980;303:1038-41.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">EUROASPIRE I and II Group: Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention through Intervention to Reduce Events. Lancet 2001; 357: 995-1001.</mixed-citation><mixed-citation xml:lang="en">EUROASPIRE I and II Group: Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention through Intervention to Reduce Events. Lancet 2001; 357: 995-1001.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Eur Heart J 2001; 22: 554-72.</mixed-citation><mixed-citation xml:lang="en">EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Eur Heart J 2001; 22: 554-72.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kotseva K, Wood D, De Backer G, De Bacquer D. et al; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16(2):121-37.</mixed-citation><mixed-citation xml:lang="en">Kotseva K, Wood D, De Backer G, De Bacquer D. et al; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16(2):121-37.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Panchenko EP, Belenkov YN Characteristics and outcomes in outpatients with atherothrombosis in the Russian Federation (based on the international registry REACH). Kardiologiya 2008; 2: 17-24. Russian (Панченко Е.П., Беленков Ю.Н. Характеристика и исходы атеротромбоза у амбулаторных больных в Российской Федерации (по материалам международного регистра REACH). Кар-диология 2008; 2: 17-24).</mixed-citation><mixed-citation xml:lang="en">Panchenko EP, Belenkov YN Characteristics and outcomes in outpatients with atherothrombosis in the Russian Federation (based on the international registry REACH). Kardiologiya 2008; 2: 17-24. Russian (Панченко Е.П., Беленков Ю.Н. Характеристика и исходы атеротромбоза у амбулаторных больных в Российской Федерации (по материалам международного регистра REACH). Кар-диология 2008; 2: 17-24).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Posnenkova OM, Kiselev AR, Korotin AS, et al. Public Report on the quality of medical care for patients with stable coronary heart disease and chronic heart failure 2013: data register of ischemic heart disease and chronic heart failure in the city of Saratov. Kardio-IT 2014; 1: 0402. Russian (Посненкова О.М., Киселев А.Р., Коротин А.С., и др. Публичный отчет о качестве медицинской помощи боль-ным со стабильной ишемической болезнью сердца и хронической сердечной недостаточностью в 2013 году: данные регистра ишемической болезни сердца и хронической сердечной недо-статочности по г. Саратову. Кардио-ИТ 2014; 1: 0402).</mixed-citation><mixed-citation xml:lang="en">Posnenkova OM, Kiselev AR, Korotin AS, et al. Public Report on the quality of medical care for patients with stable coronary heart disease and chronic heart failure 2013: data register of ischemic heart disease and chronic heart failure in the city of Saratov. Kardio-IT 2014; 1: 0402. Russian (Посненкова О.М., Киселев А.Р., Коротин А.С., и др. Публичный отчет о качестве медицинской помощи боль-ным со стабильной ишемической болезнью сердца и хронической сердечной недостаточностью в 2013 году: данные регистра ишемической болезни сердца и хронической сердечной недо-статочности по г. Саратову. Кардио-ИТ 2014; 1: 0402).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Pfeffer AM, McMurray J, Leizorovicz A, et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-50.</mixed-citation><mixed-citation xml:lang="en">Pfeffer AM, McMurray J, Leizorovicz A, et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-50.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Martsevich SY, Ginzburg ML, Kutishenko NP, et al. The dynamics of pre-hospital care of patients with acute coronary syndrome from 2005 to 2014. According to the LIS register. Ration Pharmacother Cardiol 2014; 10 (6): 631-3. Russian (Марцевич С.Ю., Гинзбург М.Л., Кутишенко Н.П., и др. Ди-намика догоспитальной терапии больных с острым коронарным синдромом с 2005 по 2014 гг. по данным регистра ЛИС. Рациональная Фармакотерапия в Кардиологии 2014;10(6):631-3).</mixed-citation><mixed-citation xml:lang="en">Martsevich SY, Ginzburg ML, Kutishenko NP, et al. The dynamics of pre-hospital care of patients with acute coronary syndrome from 2005 to 2014. According to the LIS register. Ration Pharmacother Cardiol 2014; 10 (6): 631-3. Russian (Марцевич С.Ю., Гинзбург М.Л., Кутишенко Н.П., и др. Ди-намика догоспитальной терапии больных с острым коронарным синдромом с 2005 по 2014 гг. по данным регистра ЛИС. Рациональная Фармакотерапия в Кардиологии 2014;10(6):631-3).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Shalnova SA, Deev LD. "Lessons of OSCAR - epidemiology and therapy especially high-risk patients in clinical practice 2005-2006". Kardiovaskulyarnaya Terapiya i Profilaktika 2007; 6 (1): 47-53. Russian (Шальнова С.А., Деев Л.Д. «Уроки исследования ОСКАР – эпидемиология и особенности терапии пациентов высокого риска в реальной клинической практике 2005-2006г». Кардио-васкулярная Терапия и Профилактика 2007; 6(1):47-53).</mixed-citation><mixed-citation xml:lang="en">Shalnova SA, Deev LD. "Lessons of OSCAR - epidemiology and therapy especially high-risk patients in clinical practice 2005-2006". Kardiovaskulyarnaya Terapiya i Profilaktika 2007; 6 (1): 47-53. Russian (Шальнова С.А., Деев Л.Д. «Уроки исследования ОСКАР – эпидемиология и особенности терапии пациентов высокого риска в реальной клинической практике 2005-2006г». Кардио-васкулярная Терапия и Профилактика 2007; 6(1):47-53).</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Aronov DM. How to effectively use statins. Meditsinskiy Sovet 2007; 1: 41-5. Russian (Аронов Д.М. Как эффективно применять статины. Медицинский Совет 2007; 1: 41-5).</mixed-citation><mixed-citation xml:lang="en">Aronov DM. How to effectively use statins. Meditsinskiy Sovet 2007; 1: 41-5. Russian (Аронов Д.М. Как эффективно применять статины. Медицинский Совет 2007; 1: 41-5).</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Shalnova SA, Deev AD, Karpov YA. Arterial hypertension and coronary heart disease in actual practice cardiologist. Kardiovaskulyarnaya Terapiya i Profilaktika 2006; 5 (2): 73-80. Russian (Шально-ва С.А., Деев А.Д., Карпов Ю.А. Артериальная гипертония и ишемическая болезнь сердца в ре-альной практике врача-кардиолога. Кардиоваскулярная Терапия и Профилактика 2006; 5(2): 73-80).</mixed-citation><mixed-citation xml:lang="en">Shalnova SA, Deev AD, Karpov YA. Arterial hypertension and coronary heart disease in actual practice cardiologist. Kardiovaskulyarnaya Terapiya i Profilaktika 2006; 5 (2): 73-80. Russian (Шально-ва С.А., Деев А.Д., Карпов Ю.А. Артериальная гипертония и ишемическая болезнь сердца в ре-альной практике врача-кардиолога. Кардиоваскулярная Терапия и Профилактика 2006; 5(2): 73-80).</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">EUROASPIRE IV reveals success and challenges in secondary prevention of CVD across Europe. Available at: http://www.escardio.org/about/press/press-releases/esc13-amsterdam/Pages/euroaspireiv-success-challenges-secondary-prevention-CVD-europe.aspx. Accessed by 20.03.2015.</mixed-citation><mixed-citation xml:lang="en">EUROASPIRE IV reveals success and challenges in secondary prevention of CVD across Europe. Available at: http://www.escardio.org/about/press/press-releases/esc13-amsterdam/Pages/euroaspireiv-success-challenges-secondary-prevention-CVD-europe.aspx. Accessed by 20.03.2015.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
